Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Millions of Americans struggle with weight management, and GLP-1 receptor agonists have emerged as a powerful tool for sustainable weight loss. But not everyone is a candidate for these medications, and understanding your eligibility is the first step toward deciding if GLP-1 treatment is right for you. PlexusDx helps patients navigate qualification criteria and find a treatment path tailored to their individual health profile.

BMI Requirements for GLP-1 Eligibility

Body mass index (BMI) is a primary factor in determining GLP-1 candidacy. Most patients with a BMI of 30 or higher (classified as obese) qualify for treatment, while those with a BMI of 27 to 29.9 (overweight category) may qualify if they have weight-related health complications. Your BMI is calculated by dividing your weight in kilograms by your height in meters squared, and it serves as a starting benchmark for evaluating treatment suitability.

However, BMI alone does not tell the complete story. A healthcare provider considers your overall metabolic health, family history, and individual circumstances when assessing whether GLP-1 therapy aligns with your needs. PlexusDx connects you with clinicians who evaluate the full picture of your health to ensure treatment matches your specific situation.

Medical Conditions That Support GLP-1 Qualification

Patients with weight-related medical conditions often qualify for GLP-1 treatment even at lower BMI thresholds. Type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, and heart disease are common conditions that strengthen the case for GLP-1 therapy. These comorbidities indicate that weight loss could meaningfully improve overall health outcomes and reduce medication burden.

Insulin resistance and metabolic syndrome are additional indicators that a patient may benefit from GLP-1 treatment. These conditions reflect deeper dysregulation in how the body processes glucose and manages weight, making GLP-1 medications particularly effective for metabolic correction. PlexusDx clinicians evaluate your complete medical profile to identify whether these factors apply to your situation.

Age, Pregnancy, and Special Population Considerations

GLP-1 medications are generally appropriate for adults aged 18 and older who meet weight and health criteria. Patients should not be pregnant, planning pregnancy in the near term, or breastfeeding, as safety data in these populations remains limited. Additionally, those with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 are not candidates for GLP-1 treatment.

Older adults and patients with kidney or liver disease may still qualify but require closer monitoring and dose adjustments. PlexusDx screening includes questions about your medical history, current medications, and family health patterns to identify any contraindications before treatment begins. This thorough approach ensures safety and efficacy across diverse patient populations.

How PlexusDx Assesses Your GLP-1 Readiness

PlexusDx uses a streamlined qualification process that combines your health metrics with genetic insights through the Precision Peptide Genetic Test. This test examines key genetic variants such as GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313, which influence how your body responds to GLP-1 therapy. Understanding your genetic predispositions helps PlexusDx clinicians select the most effective medication and dosing strategy for your metabolism.

Once you complete the initial screening, PlexusDx connects you with a licensed clinician who reviews your BMI, medical history, current medications, and genetic profile. If you qualify, you gain access to compounded semaglutide injections starting at $149 per month from licensed 503A compounding pharmacies. Treatment can begin quickly, and your dose may need to go up over time—but your price won't, ensuring transparent, predictable costs throughout your weight loss journey.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the minimum BMI needed to qualify for GLP-1 treatment at PlexusDx?

Most patients with a BMI of 30 or higher qualify for GLP-1 treatment. Those with a BMI between 27 and 29.9 may qualify if they have weight-related health conditions such as diabetes, high blood pressure, or sleep apnea. PlexusDx clinicians evaluate your complete health picture to determine eligibility.

Can I qualify for GLP-1 if I don't have diabetes or other chronic diseases?

Yes. Many patients without diabetes qualify for GLP-1 therapy based on BMI alone if they meet the obesity threshold (BMI ≥ 30) or are overweight with metabolic concerns. PlexusDx focuses on your individual health goals and metabolic markers rather than requiring a specific disease diagnosis.

How does the Precision Peptide Genetic Test help determine my GLP-1 candidacy?

The Precision Peptide Genetic Test examines 14 pathways and 49 peptides to reveal how your genetics influence appetite regulation, glucose metabolism, and fat storage. Results inform which GLP-1 medication and dosing strategy will work best for your body.

Are there any medical conditions that make me ineligible for GLP-1?

Yes. A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 makes GLP-1 treatment unsuitable. Pregnancy, plans to become pregnant soon, and breastfeeding are also contraindications. PlexusDx screening identifies these factors before treatment starts.

What is the cost if I qualify for GLP-1 treatment through PlexusDx?

Compounded semaglutide injections start at $149 per month and come from licensed 503A compounding pharmacies. PlexusDx serves all 50 states with no insurance required and no membership fees. Treatment is HSA and FSA eligible, making it accessible and affordable for most patients.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves